Ribociclib (RIB) plus letrozole (LET) in subgroups of special clinical interest with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial
No Thumbnail Available
Identifiers
Date
2020-09-01
Authors
Cottu, P. H.
Ring, A.
Marchetti, P.
Cardoso, F.
Salvador, J.
Neven, P.
Papazisis, K.
Campone, M.
Bachelot, T.
Menon-Singh, L.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
